BD FACSVia™ System

Designed for rapid detection of HLA-B27 antigen expression

An innovative system that provides reliability and consistency for the detection of HLA-B27

With the BD FACSVia™ system, clinical laboratories can obtain accurate and consistent results for the rapid detection of HLA-B27 antigen expression in erythrocyte-lysed whole blood, that can be used with other clinical findings to support diagnosis.

• BD™ HLA-B27 reagent kit
• Intuitive BD FACSVia™ clinical software with HLA-B27 predefined templates to ensure reproducible and consistent results
• Automated instrument setup for predictable and reproducible sample analysis
• Automated instrument QC to minimize user involvement and ensure instrument performance
The BD FACSVia is an easy and intuitive system that improves clinical laboratory workflow efficiency

**Automated processes at the push of a button**
- Automated instrument QC in less than 5 minutes
- Automated instrument setup and shutdown
- Intuitive user interface

**Improved sample turnaround time (TAT)**
- Simplified sample analysis with preloaded BD FACSVia HLA-B27 templates
- Easy access to data collection, analysis, and reporting functions, all in one screen
- Data files that can be exported in .fcs format for further analysis
- Improved sample throughput with the optional BD FACSVia™ Loader
- Optional BD FACSLink™ software for lab LIS connectivity helps minimize data entry transcription errors

**HLA-B27 Kit**

The presence of HLA-B27 antigen is strongly associated with ankylosing spondylitis (AS), a chronic inflammatory disease of the axial musculoskeletal system, and a few other rheumatic disorders (Reiter’s syndrome, acute anterior uveitis, and inflammatory bowel disease).

HLA-B27 testing is routinely used to screen for AS since 90% of patients with AS have the HLA-B27 surface antigen compared to only 8% of healthy individuals.

The BD™ HLA-B27 kit provides a qualitative two-color direct immunofluorescence method for the rapid detection of HLA-B27 antigen expression in erythrocyte-lysed whole blood (LWB).

**HLA-B27 procedure**

**Principles of this procedure**
- The Anti–HLA-B27 FITC/CD3 PE monoclonal antibody reagent is added to human whole blood
- The fluorochrome-labeled antibodies bind specifically to leucocyte surface antigens
- The stained samples are treated with BD FACS™ lysing solution to lyse erythrocytes
- The samples are washed and fixed before flow cytometric analysis

For information related to the cell suspension preparation, see the IFU for the BD HLA-B27 reagent kit.
BD FACS®Via clinical software with HLA-B27 predefined templates provide reliable results

**Ordering information**

<table>
<thead>
<tr>
<th>Description</th>
<th>Tests</th>
<th>Cat. No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>BD™ HLA-B27 Kit</td>
<td>50</td>
<td>340183</td>
</tr>
</tbody>
</table>

### Results Summary

- **Total events**: 9808
- **CD3+ events**: 2239
- **CD3+ Percent of total events**: 22.8%
- **Decision Marker/Reagent Suffix**: 148
- **Sample Median**: 138
- **Conclusion**: Negative